Ho D D, Neumann A U, Perelson A S, Chen W, Leonard J M, Markowitz M
Aaron Diamond AIDS Research Center, NYU School of Medicine, New York 10016.
Nature. 1995 Jan 12;373(6510):123-6. doi: 10.1038/373123a0.
Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.
用1型人类免疫缺陷病毒（HIV-1）蛋白酶抑制剂ABT-538治疗受感染患者，可使血浆HIV-1水平呈指数下降（平均半衰期为2.1±0.4天），并使CD4淋巴细胞计数大幅上升。对HIV-1产生和清除以及CD4淋巴细胞更新的最低估计表明，HIV-1在体内的复制是持续且高效的，促使CD4淋巴细胞快速更新。
